Adalimumab (anti-TNF-α) Reference: HY-P9908A Adalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
Labetuzumab Reference: HY-P99160 Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy.
Iscalimab Reference: HY-P99670 Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases.
Lerdelimumab Reference: HY-P99695 Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research.
Ziltivekimab Reference: HY-P99505 Ziltivekimab (COR-001) is a human anti-IL-6 monoclonal antibody that is effective in reducing serum CRP. Ziltivekimab has anti-inflammatory activity and may be used in studies of chronic systemic inflammation and cardiovascular disease associated with CKD.
Pivekimab Reference: HY-P99234 Pivekimab is a human IgG1 monoclonal antibody targeting interleukin 3 (IL-3) and CD123. Pivekimab can be used in the study of blastocytic plasmacytoid dendritic cell tumor (BPDCN).